XL Construction’s Post

We are thrilled to welcome Ari Landon, PhD, MBA to the Elevate Team as Vice President, Life Sciences & Healthcare! Dr. Landon brings a robust life science background, including therapeutics, biotechnology, and medical device development. His extensive experience spans entrepreneurship and investing, positioning him to drive continued growth in the Indiana startup ecosystem. To learn more about Ari, you can find a link to the press release in the comments. #InnovationCapitaloftheWorld #IndianaLifeSciences

🔬 Top Fundraises in Life Science Tools and Diagnostics 2024 According to an analysis by 360Dx the second half of 2024 saw increased private investment momentum in life science tools and diagnostics, with $1.51 billion raised across 49 deals—a notable 9% increase from the previous year. 🔗 (Paywall): https://lnkd.in/dqzMX6WT 💡 Key Trends and Insights 1️⃣ Lower Valuations Drive Activity: Many firms have come to terms with recalibrated valuations, opening the door for increased deal flow. 2️⃣ Sector Divergence: Life science tools firms are attracting more capital than diagnostics which continues to struggle in the funding landscape, reflecting a multi-year trend of limited investor enthusiasm. 3️⃣ AI and Innovation: Companies integrating AI technologies, particularly in life science tools, are seeing heightened investor interest for their potential to deliver deeper insights and higher client impact. 📈 Notable Fundraises • Element Biosciences led the pack with a $277M Series D round, reflecting the sustained promise of sequencing innovation. • BillionToOne continued its strong fundraising year with a $140M non-dilutive financing, signaling confidence in liquid biopsy applications. • Oxford Nanopore Technologies and Cytovale also raised significant rounds, highlighting growth in portable sequencing and advanced diagnostics. 🔮 Looking Ahead to 2025 The diverse range of fundraises in H2 2024 reflects a sector regaining balance. As innovation continues, companies developing scalable, de-risked, and high-impact solutions are likely to attract more capital in the coming year. 👉 What are your predictions for 2025? #LifeSciences #Diagnostics #Funding #PrivateEquity #BiotechInvestments #Innovation

Medtech News: Orange County, CA based Nidus Biomedical, a medtech incubator, announces its acquisition of Alta Biomaterials and subsequent rebranding to ALTA Biomed https://lnkd.in/gQFWrmmD #medtech #acquisition #medicaldevice #news

"Life science tools firms are attracting more capital than diagnostics which continues to struggle in the funding landscape, reflecting a multi-year trend of limited investor enthusiasm". Jason Gilder

What 2024 Fundraising Trends in Life Sciences Tools & Diagnostics Tell Us About 2025 💡 … … .. Looking at the top 10 fundraises in Dx and Tools for H2 2024, it’s clear that investor appetite is evolving toward cutting-edge innovation in diagnostics and tools. Here’s a snapshot of the companies leading the charge: Element Biosciences ($277M): Advances in high-throughput sequencing. BillionToOne ($140M): Molecular diagnostics and NIPT. Oxford Nanopore Technologies ($103.5M): Long-read sequencing technologies. Cytovale ($100M): Rapid diagnostics for critical conditions. Nuclera ($75M): Protein engineering for biotech applications. Truvian Health ($74M): Affordable, high-throughput diagnostics. Constructive Bio ($58M): Synthetic biology innovations. Inflammatix, Inc. ($57M): Biomarker-based diagnostics for infection. Spear Bio ($45M): Cutting-edge protein assays. Nomic Bio ($42M): Proteomics platforms for drug discovery. What Does This Tell Us? 1️⃣ Precision and Accessibility: Companies like BillionToOne and Truvian Health reflect a strong investor focus on scalable, accessible diagnostics for broader populations. 2️⃣ Synthetic and Computational Biology Boom: With players like Nuclea and Constructive Bio attracting significant funding, synthetic biology and protein engineering remain hot areas for growth. 3️⃣ Speed to Insights: Firms such as Cytovale and Inflammatix highlight the push toward faster, actionable diagnostics, catering to the need for rapid decision-making in critical care and infectious disease management. 4️⃣ Platform Plays: Oxford Nanopore and Element Biosciences prove that sequencing and proteomics platforms are still investor favorites, likely due to their ability to power innovations across drug discovery, diagnostics, and beyond. What Can We Expect in 2025? Expect platform convergence: AI, proteomics, and molecular diagnostics could increasingly blend to create comprehensive solutions for healthcare and drug R&D. Investors are likely to double down on companies offering transformational technologies with immediate clinical and commercial applications. Thanks Maximilian Schmid, M.D. for creating this very insightful post! _________ Love ❤️ this post? Add your comments 💭, re-share ♻ it with your network, follow me 🔔 for more posts like this, and DM me 📩 if you want to deep dive on this topic!

Ten years ago today, we started Kairos Ventures to create moments in time (Kairos is a Greek word which means special moments in time which result in good things happening) where breakthroughs in science, from our nations top scientists at Universities, could change the world.   Today, our companies have raised some 1.3 billion dollars and have demonstrated and are starting to commercialize many breakthroughs. From the world’s first plasma ignition technology that can help improve MPG of cars by 25%, to the world’s first plastic heart valves installed in humans, to the first company to develop inexpensive chemistry to produce pheromones for insect mating disruption, to a new outpatient treatment that will break up kidney stones, to a drone that has folding wings,  to multiple drugs in phase 2 trials for cancer treatments, to an etching technology that can etch surfaces at a molecular level, to a company that can grow vascularized human tissue to test drug efficacy and reduce all drug development times by years, we focus on world firsts.   It’s not easy doing what we do. But, our mission is to find the best and brightest, and help them, so together, we can change the world.   To all of our university partners, founders, investors and team members: we salute you and appreciate your support. None of this would have been possible without you. #KairosVentures #Innovation #WorldFirsts #TranslatingResearch Transient Plasma Systems, Foldax Inc., Provivi, Inc., Avvio Medical, Inc., PteroDynamics Inc., NanoClear Technologies, Vivodyne, Actuate Therapeutics, Inc.

Utah's vibrant life sciences industry will take center stage at the 2025 Life Sciences Day on the Hill, highlighting the state's remarkable growth in healthcare innovation. The January 30th event, hosted by BioUtah in partnership with the Utah Life Sciences Innovation Caucus, will transform the State Capitol's rotunda into a dynamic showcase of cutting-edge medical technologies. Over 25 leading companies will display their groundbreaking work, representing a diverse range of disciplines from medical devices to biotechnology. This gathering provides a critical platform for industry innovators to directly engage with state legislators. 'Our industry is driving significant economic impact,' said Kelvyn Cullimore, BioUtah's president and CEO. 'We're not just creating jobs, but developing technologies that fundamentally improve patient care.' Utah's life sciences sector has become an economic powerhouse, generating $22 billion in GDP and employing 180,000 professionals. The event underscores the state's emergence as a national healthcare innovation hub. Participating organizations include prominent names like ARUP Laboratories, Edwards Lifesciences, Intermountain Health, and the University of Utah, representing the breadth and depth of Utah's biomedical ecosystem. This showcase represents more than a networking opportunity—it's a testament to Utah's commitment to advancing healthcare through technological innovation. #LifeSciences #HealthTech #UtahInnovation

WELCOME NEW MEMBER, The RI Life Science Hub ! They are responsible for administering a $45 million three-year appropriation allocated through the state legislation and are now focused on creating jobs in the life sciences, driving innovation, and ensuring our workforce is ready to compete in the global life science industry – all for the betterment of human health and wellness. The legislation defines key focus areas for the Hub, including: · Supporting medical and scientific advancements through collaboration with companies specializing in diverse fields such as biopharmaceuticals, medical devices, biomedical technology, biomanufacturing, cell and gene therapies, health software and AI, biomedical engineering, genomics, diagnostics, and the broader life sciences to foster the development of cutting-edge medical breakthroughs. · Targeted investment initiatives that provide strategic funding for a commercial life science incubator through grants, tax credits, and incentives to support and grow Rhode Island-based life science companies. These investments are designed to enhance economic and workforce development within the state and position Rhode Island to compete in national and global life science sectors. Learn more: https://buff.ly/3zU6jQA #RIBioMember #RIBioMembers #LifeSciences #Biotech #RhodeIsland #RILSH

Exciting News from Nidus Biomedical! We’re thrilled to announce the acquisition of Alta Biomaterials, an organization that has led the field in best in class, drug-free, anti-thrombotic coatings . This partnership marks a pivotal step forward in our mission to drive innovation in #medtech and #healthcare. Together, we are relaunching as ALTA Biomed where we’re set to amplify our capabilities, accelerate groundbreaking discoveries, and deliver transformative solutions to the industry. Stay tuned for more updates as we embark on this next chapter! In the meantime, if you're interested in learning more, please reach out to Alta's VP of R&D Chris Nocera #InnovationInBiotech #NidusBiomedical #AltaBiomed #Acquisition #HealthcareInnovation

Claret has a long track-record of investing in life sciences, supporting innovative businesses across the sector, from therapeutics to medical devices to health IT. Investments to date include the likes of Abivax, Cardiac Dimensions, Deciphex, Endomag, and most recently, Neurent Medical. 📽️ In this video, Joey Mason, Venture Partner with over 30 years' experience in the sector, shares his insights and highlights how life science companies can use venture debt to fuel growth. 🚀 If you're an early or growth stage life science company looking to secure €5-50M growth debt funding, get in touch with the team at contact@claret-capital.com! #lifesciences #growth #investment #growthdebt #venturedebt